Replies to post #137846 on Biotech Values

[mcbio]

My understanding is they are working on purine and pyrimidine nucleotides. Any idea which one is partnered?

Not sure on that. Will have to do some more digging. They did give a lot more buzz to the unpartnered nuke, but I guess that's to be expected.

I'm not sure about the trial design [TMC435] but they claim sufficient activity in all genotypes except GT3.

That's correct. And they claim there is some activity against GT3 but not on the level compared to the other genotypes.

I think you will do well with this company once battle lines between developers are drawn this year.

I think the TMC435+GS7977 initial results in 4Q12 will go a long way towards determining this. I think Medivir's valuation is a combo of the Euro crisis and perhaps skepticism of a PI+nuke combo given IDIX's issues with their combo. Can Medivir and GILD put to rest those concerns and show that the IDIX issues were specific to their HCV drugs and show that this combo adds meaningfully to the efficacy of GS7977 alone? That is what needs to be answered.